Calliditas Therapeutics AB (CALT)
22.40
-0.19
(-0.84%)
USD |
NASDAQ |
May 15, 16:00
22.40
0.00 (0.00%)
After-Hours: 20:00
Calliditas Therapeutics Profit Margin (Quarterly): -4.07% for Dec. 31, 2023
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -4.07% |
| September 30, 2023 | -57.15% |
| June 30, 2023 | -34.13% |
| December 31, 2022 | -0.86% |
| September 30, 2022 | -3.50% |
| June 30, 2022 | -300.4% |
| March 31, 2022 | -416.3% |
| December 31, 2021 | -702.9% |
| September 30, 2021 | 5.34% |
| Date | Value |
|---|---|
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | -42.61K% |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | -13.44K% |
| December 31, 2019 | -49.48% |
| September 30, 2019 | |
| June 30, 2019 | 60.16% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-42.61K%
Minimum
Dec 2020
60.16%
Maximum
Jun 2019
-4.43K%
Average
-49.48%
Median
Dec 2019
Profit Margin (Quarterly) Benchmarks
| DBV Technologies SA | -- |
| Cellectis SA | -15.15K% |
| Adaptimmune Therapeutics PLC | -20.74K% |
| Akari Therapeutics PLC | -- |
| Biodexa Pharmaceuticals Plc | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -52.72% |
| Return on Assets | -16.25% |
| Return on Invested Capital | -22.38% |
| Gross Profit Margin (Quarterly) | 95.06% |
| Operating Margin (Quarterly) | 1.20% |
| Return on Net Operating Assets | -16.65% |